1. Absence of Relationship between Mitochondrial DNA Haplogroups and Cisplatin-Induced Hearing Loss
- Author
-
D. Graterol, C. Garcia-Vaquero, M. I. Rochera-Villach, Cristina Mir, Alex Lyakhovich, Matilde E. Lleonart, I. Braña, Juan Lorente, and A. N. Pardo
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Article Subject ,Hearing loss ,lcsh:Surgery ,Audiology ,Haplogroup ,03 medical and health sciences ,Ototoxicity ,Internal medicine ,otorhinolaryngologic diseases ,Medicine ,Cisplatin ,Cardiotoxicity ,medicine.diagnostic_test ,business.industry ,lcsh:RD1-811 ,General Medicine ,lcsh:Otorhinolaryngology ,medicine.disease ,lcsh:RF1-547 ,030104 developmental biology ,Cohort ,medicine.symptom ,Audiometry ,business ,Research Article ,Human mitochondrial DNA haplogroup ,medicine.drug - Abstract
Background.Many drugs used for cancer chemotherapy produce reactive oxygen species, thus leading to various complications including nephrotoxicity, cardiotoxicity, and ototoxicity.Objective.We have provided a haplogroup analysis of a cohort of cancer patients treated with chemotherapy and compared factors associated with associated hearing loss.Study Design and Methods.This observational cohort study includes a pure-tone audiometry of the patients who underwent chemotherapeutic treatment. Medical history, presence of risk factors for hearing loss, toxic habits, and association with haplogroups have been determined.Results.40% of patients developed hearing loss after administration of cisplatin, which was bilateral and symmetrical and of high frequencies. The most frequent haplogroup was H with a slight overexpression of groups V and K and a low frequency of groups J and T. No association of the haplogroup types with the hearing loss has been found; however age was revealed as an important determining factor.Conclusions.Ototoxicity caused by cisplatin is manifested as bilateral, symmetrical, and predominantly high frequency hearing loss. Although we did not find a strong correlation of haplogroups with ototoxicity, our results revealed the existence of a risk group of elderly patients over 60, which are more susceptible to hearing loss induced by cisplatin, than young adults, regardless of preexisting hearing loss.
- Published
- 2017
- Full Text
- View/download PDF